OSTEOARTHRITIS
Tanezumab effectively and safely reduces OA hip pain and improves physical function
Arthritis Rheum. 2013 Jul;65(7):1795-803. doi: 10.1002/art.37950627 patients with hip osteoarthritis (OA) were randomized to receive either 2.5 mg, 5 mg, or 10 mg doses of intravenous tanezumab (monoclonal antibody against nerve growth factor) or a placebo. The purpose was to compare each treatment's efficacy in lowering pain. After 32 weeks, results indicated that patients who were treated with tanezumab had significantly greater improvements in pain and physical function compared to patients in the placebo group, with 10 mg doses providing the greatest improvements. However, although not statistically significant, the incidence of adverse events was greater in patients of the tanezumab groups in comparison to the placebo group.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
